Lorus Therapeutics has announced a plan for a new clinical investigation of GTI-2040 as a single-agent in patients with high grade myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
These two disease conditions may represent a continuum in malignant progression of the abnormal production of blood cells in the bone marrow that results in a rapidly progressing form of leukemia. Patients that have MDS which progresses to AML have been identified as an especially high-risk group for poor survival.